Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes

Diabetes Care

Volumn 39, Issue 8, 2016, Pages 1408-1415

  Digenio, Andres ^a   Dunbar, Richard L ^b   Alexander, Veronica J ^c   Hompesch, Marcus ^d   Morrow, Linda ^d   Lee, Richard G ^c   Graham, Mark J ^c   Hughes, Steven G ^c   Yu, Rosie ^c   Singleton, Walter ^c   Baker, Brenda F ^c   Bhanot, Sanjay ^c   Crooke, Rosanne M ^c  

^a Akcea Therapeutics   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c ISIS PHARMACEUTICALS   (United States)

^d Profil Institute for Clinical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; APOLIPOPROTEIN C3; FRUCTOSAMINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; TRIACYLGLYCEROL; VOLANESORSEN; ANTISENSE OLIGONUCLEOTIDE; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPERINSULINEMIC-EUGLYCEMIC CLAMP TECHNIQUE; HYPERTRIGLYCERIDEMIA; INJECTION SITE REACTION; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; BLOOD; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED;

AGED; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN C-III; BIOMARKERS; BLOOD GLUCOSE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; MALE; MIDDLE AGED; OLIGONUCLEOTIDES, ANTISENSE; TRIGLYCERIDES;

EID: 84980396029     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-0126     Document Type: Article

References (40)

1. von Eckardstein A, Sibler RA. Possible contributions of lipoproteins and cholesterol to the pathogenesis of diabetes mellitus type 2. Curr Opin Lipidol 2011; 22:26-32
2. Wu L, Parhofer KG. Diabetic dyslipidemia. Metabolism 2014; 63:1469-1479
3. Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. J Clin Lipidol 2014; 8:473-488
4. Stone NJ, Robinson JG, Lichtenstein AH, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129(Suppl. 2):S1-S45
5. Catapano AL, Reiner Z, De Backer G, et al.; European Society of Cardiology (ESC); European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217:3-46
6. Bruckert E, Labreuche J, Deplanque D, Touboul PJ, Amarenco P. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. J Cardiovasc Pharmacol 2011; 57:267-272
7. Ginsberg HN, Huang LS. The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. J Cardiovasc Risk 2000; 7:325-331
8. Pétremand J, Puyal J, Chatton JY, et al. HDLs protect pancreatic β-cells against ER stress by restoring protein folding and trafficking. Diabetes 2012; 61:1100-1111
9. Holmberg R, Refai E, Höög A, et al. Lowering apolipoprotein CIII delays onset of type 1 diabetes. Proc Natl Acad Sci U S A 2011; 108:10685-10689
10. Chan DC, Chen MM, Ooi EMM, Watts GF. An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor? Int J Clin Pract 2008; 62:799-809
11. Ooi EMM, Barrett PHR, Chan DC, Watts GF. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci (Lond) 2008; 114:611-624
12. Lee HY, Birkenfeld AL, Jornayvaz FR, et al. Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance. Hepatology 2011; 54:1650-1660
13. Petersen KF, Dufour S, Hariri A, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med 2010; 362: 1082-1089
14. Verrijken A, Beckers S, Francque S, et al. A gene variant of PNPLA3, but not of APOC3, is associated with histological parameters of NAFLD in an obese population. Obesity (Silver Spring) 2013; 21:2138-2145
15. Crosby J, Peloso GM, Auer PL, et al.; TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 2014; 371:22-31
16. Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med 2014; 371:32-41
17. Cohen JC, Stender S, Hobbs HH. APOC3, coronary disease, and complexities of Mendelian randomization. Cell Metab 2014; 20:387-389
18. Graham MJ, Lee RG, Bell TA 3rd, et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res 2013; 112:1479-1490
19. Gaudet D, Alexander VJ, Baker BF, et al. Antisense inhibition of apolipoprotein C-III in patients with hypertriglycereidemia. N Engl J Med 2015; 373:438-447
20. Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med 2014; 371:2200-2206
21. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008; 294:E15-E26
22. Krentz AJ, Heinemann L, Hompesch M. Methods for quantifying insulin sensitivity and determining insulin time-action profiles. In Translational Research Methods for Diabetes, Obesity, and Cardiometabolic Drug Development: Focus on Early Phase Studies. Krentz AJ, Heinemann L, Hompesch M, Eds. New York, Springer, 2015, p. 3-44
23. Hokanson JE, Kinney GL, Cheng S, Erlich HA, Kretowski A, Rewers M. Susceptibility to type 1 diabetes is associated with ApoCIII gene haplotypes. Diabetes 2006; 55:834-838
24. Florez H, Mendez A, Casanova-Romero P, et al. Increased apolipoprotein C-III levels associated with insulin resistance contribute to dyslipidemia in normoglycemic and diabetic subjects from a triethnic population. Atherosclerosis 2006; 188:134-141
25. Alaupovic P, Bard JM, Tavella M, Shafer D. Identification of apoB-containing lipoprotein families in NIDDM. Diabetes 1992; 41(Suppl. 2): 18-25
26. Blackett P, Sarale DC, Fesmire J, Harmon J, Weech P, Alaupovic P. Plasma apolipoprotein C-III levels in children with type I diabetes. South Med J 1988; 81:469-473
27. Qamar A, Khetarpal SA, Khera AV, Qasim A, Rader DJ, Reilly MP. Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics. Arterioscler Thromb Vasc Biol 2015; 35:1880-1888
28. Batal R, Tremblay M, Barrett PH, et al. Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects. J Lipid Res 2000; 41:706-718
29. Schonfeld G, George PK, Miller J, Reilly P, Witztum J. Apolipoprotein C-II and C-III levels in hyperlipoproteinemia. Metabolism 1979; 28: 1001-1010
30. Selvin E, Rawlings AM, Lutsey PL, et al. Fructosamine and glycated albumin and the risk of cardiovascular outcomes and death. Circulation 2015; 132:269-277
31. Ginsberg HN Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106:453-458
32. Shulman GI Cellular mechanisms of insulin resistance. J Clin Invest 2000; 106:171-176
33. Pedrini MT, Niederwanger A, Kranebitter M, et al. Postprandial lipaemia induces an acute decrease of insulin sensitivity in healthy men independently of plasma NEFA levels. Diabetologia 2006; 49:1612-1618
34. Johnson NA, Stannard SR, Rowlands DS, et al. Short-term suppression of plasma free fatty acids fails to improve insulin sensitivity when intramyocellular lipid is elevated. Diabet Med 2006; 23:1061-1068
35. Caron S, Verrijken A, Mertens I, et al. Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 2011; 31:513-519
36. Altomonte J, Cong L, Harbaran S, et al. Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J Clin Invest 2004; 114:1493-1503
37. Chan DC, Watts GF, Barrett PHR, Mamo JCL, Redgrave TG. Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity. Clin Chem 2002; 48:278-283
38. Kassai A, Muniyappa R, Levenson AE, et al. Effect of leptin administration on circulating apolipoprotein CIII levels in patients with lipodystrophy. J Clin Endocrinol Metab 2016; 101: 1790-1797
39. Heilbronn L, Smith SR, Ravussin E. Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus. Int J Obes Relat Metab Disord 2004; 28(Suppl. 4):S12-S21
40. Handelsman Y, Oral EA, Bloomgarden ZT, et al.; American Association of Clinical Endocrinologists. The clinical approach to the detection of lipodystrophy - an AACE consensus statement. Endocr Pract 2013; 19:107-116